Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

<p>Abstract</p> <p>Background</p> <p>The epidermal growth factor receptor (EGFR) is an established target for anti-cancer treatment in different tumour types. Two different strategies have been explored to inhibit this pivotal molecule in epithelial cancer development:...

Full description

Bibliographic Details
Main Authors: Cavazzoni Andrea, Alfieri Roberta R, Cretella Daniele, Saccani Francesca, Ampollini Luca, Galetti Maricla, Quaini Federico, Graiani Gallia, Madeddu Denise, Mozzoni Paola, Galvani Elena, La Monica Silvia, Bonelli Mara, Fumarola Claudia, Mutti Antonio, Carbognani Paolo, Tiseo Marcello, Barocelli Elisabetta, Petronini Pier Giorgio, Ardizzoni Andrea
Format: Article
Language:English
Published: BMC 2012-12-01
Series:Molecular Cancer
Subjects:
Lung cancer
EGFR
Erlotinib
Cetuximab
ADCC
Online Access:http://www.molecular-cancer.com/content/11/1/91

Internet

http://www.molecular-cancer.com/content/11/1/91

Similar Items